What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 2, Pre-Registered Trial).

What question did this study set out to answer?

Evaluate the efficacy of R-MPV combined with lenalidomide or ibrutinib for newly diagnosed PCNSL.

December 8, 2025Blood

Results of the primary end-point of the LOC-R01: A randomized phase II Study of lenalidomide and ibrutinib in association with rituximab-methotrexate procarbazine vincristin (R-MPV) as a targeted induction treatment for patients aged 18 to 65 with a newly diagnosed primary central nervous system lymphoma (PCNSL)

View Full Paper

Ask AI

Bookmark

Authors

CSCarole Soussain CHCaroline Houillier JHJessica Haddad

Discussion

Member takes

Overview

Randomized trial shows 86% and 82% complete response in PCNSL patients treated with R-MPV plus immunomodulatory drug or ibrutinib, suggesting effective induction strategies.

Key Points

Evaluate the efficacy of R-MPV combined with lenalidomide or ibrutinib for newly diagnosed PCNSL.
Randomized phase II trial of 92 patients aged 18-65 with untreated PCNSL.
Patients received 4 cycles of R-MPV plus either lenalidomide or ibrutinib.
Responses assessed post-induction via MRI according to IPCG criteria.
86% complete response rate in the lenalidomide arm and 82% in the ibrutinib arm.
74% of lenalidomide and 83% of ibrutinib patients proceeded to autologous stem cell transplantation.
Safety profiles were consistent with previous studies, confirming the feasibility of both treatments.

Cite This Study

Soussain et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236cfd3 https://doi.org/10.1182/blood-2025-58

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

Results of the primary end-point of the LOC-R01: A randomized phase II Study of lenalidomide and ibrutinib in association with rituximab-methotrexate procarbazine vincristin (R-MPV) as a targeted induction treatment for patients aged 18 to 65 with a newly diagnosed primary central nervous system lymphoma (PCNSL)

View Full Paper

Ask AI

Bookmark

Authors

CSCarole Soussain CHCaroline Houillier JHJessica Haddad

Discussion

Member takes

Overview

Randomized trial shows 86% and 82% complete response in PCNSL patients treated with R-MPV plus immunomodulatory drug or ibrutinib, suggesting effective induction strategies.

Key Points

Evaluate the efficacy of R-MPV combined with lenalidomide or ibrutinib for newly diagnosed PCNSL.
Randomized phase II trial of 92 patients aged 18-65 with untreated PCNSL.
Patients received 4 cycles of R-MPV plus either lenalidomide or ibrutinib.
Responses assessed post-induction via MRI according to IPCG criteria.
86% complete response rate in the lenalidomide arm and 82% in the ibrutinib arm.
74% of lenalidomide and 83% of ibrutinib patients proceeded to autologous stem cell transplantation.
Safety profiles were consistent with previous studies, confirming the feasibility of both treatments.

Cite This Study

Soussain et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236cfd3 https://doi.org/10.1182/blood-2025-58

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark